Role of Contrast Enhancement and Corrected Attenuation Values of Renal Tumors in Predicting Renal Cell Carcinoma (RCC) Subtypes: Protocol for a Triphasic Multi-Slice Computed Tomography (CT) Procedure

Basit Öğe Kaydı
dc.contributor.authorErtekin, Ersen
dc.contributor.authorAmasyali, Akin Soner
dc.contributor.authorErol, Bulent
dc.contributor.authorAcikgozoglu, Saim
dc.contributor.authorKucukdurmaz, Faruk
dc.contributor.authorNayman, Alaaddin
dc.contributor.authorErol, Haluk
dc.date.accessioned2024-02-23T14:31:14Z
dc.date.available2024-02-23T14:31:14Z
dc.date.issued2017
dc.departmentNEÜen_US
dc.description.abstractBackground: To distinguish RCC subtypes based on contrast enhancement features of CT images. Material/Methods: In total, 59 lesions from 57 patients were included. All patients underwent multi-slice CT imaging with a triphasic protocol, which included non-contrast, corticomedullary, nephrographic and urographic phases. Contrast enhancement features of renal masses were evaluated in terms of CT attenuation values (AV) and differences in contrast density; the aorta or renal parenchyma were evaluated based on corrected or relative values. Results: Clear cell RCC (ccRCC) showed more intense contrast enhancement than other RCC subtypes. When differentiating ccRCC from other RCC subtypes, a cut-off AV of 86-89 HU, aorta-based corrected AV of 89-95 HU and renal parenchyma-based corrected AV of 87-95 HU showed a diagnostic accuracy of 81-86%, 86-88% and 74-78%, respectively, in the corticomedullary phase. Furthermore, a cutoff of 2.42-2.72 for the relative contrast enhancement ratio, a cutoff of 2.59-2.74 for the aorta-based corrected relative contrast enhancement ratio and a cutoff of 2.63-2.76 for the renal parenchyma based attenuation ratio showed a diagnostic accuracy of 83-88%, 88-90% and 81%, respectively. Conclusions: The most reliable parameters for differentiating ccRCC from other RCC subtypes are aorta-based corrected AV and aorta-based corrected relative contrast enhancement values in the corticomedullary phase.en_US
dc.identifier.doi10.12659/PJR.901957
dc.identifier.endpage391en_US
dc.identifier.issn0137-7183
dc.identifier.issn1899-0967
dc.identifier.pmid28811845en_US
dc.identifier.scopus2-s2.0-85026749314en_US
dc.identifier.startpage384en_US
dc.identifier.urihttps://doi.org/10.12659/PJR.901957
dc.identifier.urihttps://hdl.handle.net/20.500.12452/15110
dc.identifier.volume82en_US
dc.identifier.wosWOS:000406165700001en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherInt Scientific Information Incen_US
dc.relation.ispartofPolish Journal Of Radiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCarcinomaen_US
dc.subjectRenal Cellen_US
dc.subjectContrast Mediaen_US
dc.subjectMultidetector Computed Tomographyen_US
dc.titleRole of Contrast Enhancement and Corrected Attenuation Values of Renal Tumors in Predicting Renal Cell Carcinoma (RCC) Subtypes: Protocol for a Triphasic Multi-Slice Computed Tomography (CT) Procedureen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu